Trials / Completed
CompletedNCT04035811
Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
Prospective Clinical Assessment Study in Children With Achondroplasia: The PROPEL Trial
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 271 (actual)
- Sponsor
- QED Therapeutics, a BridgeBio company · Industry
- Sex
- All
- Age
- 30 Months – 17 Years
- Healthy volunteers
- Not accepted
Summary
This is a long-term, multi-center, observational study in children 2.5 to \<17 years with achondroplasia (ACH). The objective is to evaluate growth, ACH-related medical complications, assessments of health-related quality of life, body pain, functional abilities, cognitive functions, and treatments of study participants. No study medication will be administered.
Conditions
Timeline
- Start date
- 2019-08-12
- Primary completion
- 2025-08-27
- Completion
- 2025-08-27
- First posted
- 2019-07-29
- Last updated
- 2026-04-03
Locations
32 sites across 11 countries: United States, Argentina, Australia, Canada, France, Germany, Italy, Norway, Singapore, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT04035811. Inclusion in this directory is not an endorsement.